Proteins and Peptides

22 Dec 2016 AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
21 Dec 2016 DiaMedica Announces Positive Top-Line Results from DM199 Bridging Clinical Trial
21 Dec 2016 Factor Therapeutics Announces Commencement of Phase II Trial of a Novel Topical Biologic for the Treatment of Chronic Wounds
21 Dec 2016 Hansa Medical Discontinues its Phase II Study in Acquired Thrombotic Thrombocytopenic Purpura (TTP)
19 Dec 2016 Antares Pharma Announces the Successful Completion of Teva’s Decentralized Procedure for Teriparatide Injection in Europe
19 Dec 2016 IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
19 Dec 2016 Ferring and IMAB Sign Licensing Agreement Granting IMAB Exclusive Rights in Asia to Olamkicept for the Treatment of Autoimmune Disease
19 Dec 2016 ProMetic initiates rolling submission of its Biologics License Application ("BLA") for plasminogen with U.S. FDA
17 Dec 2016 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with type 1 diabetes
16 Dec 2016 Significant Improvements in Knee Function after TPX-100 Administration in a Double-Blind, Placebo-Controlled Phase 2 Study of Knee Osteoarthritis
13 Dec 2016 Ferring Receives EU Approval for REKOVELLE® (follitropin delta)
13 Dec 2016 Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics
13 Dec 2016 Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial
12 Dec 2016 Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)
10 Dec 2016 Synergy Pharmaceuticals Announces Positive Results in First Phase 3 Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
08 Dec 2016 Horizon Pharma plc Announces Topline Results from Phase 3 Study of ACTIMMUNE® (interferon gamma-1b) in Friedreich's Ataxia
08 Dec 2016 Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease
08 Dec 2016 Avelas Presents Phase 1b Clinical Trial Data for AVB-620 at 2016 San Antonio Breast Cancer Symposium
08 Dec 2016 Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
07 Dec 2016 MolMed files a Conditional Marketing Authorisation in the European Union for NGR-hTNF
05 Dec 2016 Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes
05 Dec 2016 Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis
05 Dec 2016 BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
05 Dec 2016 AOP Orphan and PharmaEssentia Announce Pivotal Phase III Results for Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016
05 Dec 2016 Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing